- Home
- » Tags
- » Idursulfase
Top View
- Clinical Trials, Progression-Speed Differentiating Features, and Swiftness Rule of the Innovative Targets of First-In-Class Drugs
- Specialty Drug List 10-24-11
- May2013 CPG Updates
- Specialty Medications That Unitypoint at Home Specialty Pharmacy Can Provide Or Facilitate Access to and Is Subject to Change
- 1986 Senior Staff Fellow, Human Genetics Branch National Institute of Child Health and Human Developmental Bethesda, MD
- Lysosomal Storage Disorders
- Availability, Accessibility and Delivery to Patients of the 28 Orphan
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- CDER List of Licensed Biological Products With
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- NCL Red List at All NCL Trusts Except RNOH, Who Can Share Prescribing with a GP Within the Context of Their MDT OPAT Service
- Medical Policy Statement
- Idursulfase 1 .Pub
- China Rare Disease Market: Large and Untapped Opportunity
- For Peer Review Only - Page 1 of 59 BMJ Open
- Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
- Biochemical Genetics
- An Overview of the Orphan Medicines Market in Turkey Güvenç Koçkaya, MD, Msc1,*, Albert I
- Idursulfase) 2 Solution for Intravenous Infusion 3 4 WARNING 5 6 Risk of Anaphylaxis
- 5.01.576 Drugs for Rare Diseases
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Enzyme Replacement Therapy for Rare Diseases: a Review of Clinical Efficacy
- Engineering Enzymes Towards Biotherapeutic Applications Using Ancestral Sequence Reconstruction
- Presentation
- Imiglucerase in the Treatment of Gaucher Disease: a History and Perspective
- Partnerre Trigger Pharmaceuticals (At 2.6.20)
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- ABSTRACT BOOK 23Rd EAHP Congress 2018 March 21St–23Rd Sweden Gothenburg
- Enzyme Related Therapies
- Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
- Idursulfase for Enzyme-Replacement Therapy in Mucopolysaccharidosis II
- BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
- Lysosomes As a Therapeutic Target
- Enzyme Replacement Therapy (ERT) for Lysosomal Storage Disorders
- Idursulfase (Elaprase) Reference Number: ERX.SPMN.141 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
- Mandatory Specialty Drug List
- Appendix A: Medications Used in the Treatment of Inborn Errors
- USP Medicare Model Guidelines V7.0 (With Example Part D Drugs)
- Business Day November 18, 2008 the “SAFE HARBOR” STATEMENT UNDER the PRIVATE SECURITIES LITIGATION REFORM ACT of 1995
- TEXAS MEDICAID Clinical Edit Prior Authorization Enzymes
- Appendix A: Perioperative Medication Management
- Elaprase (Idursulfase)
- WHAT DOES the NEW ONTARIO PHARMACARE PLAN OFFER CHILDREN and YOUNG ADULTS with RARE DISORDERS? by Nigel S
- AHFS Pharmacologic-Therapeutic Classification System
- 11 Pdf [488 K]
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Medimpact April 2019 Specialty Drug List
- Prior Authorization — Premium
- Do Not Tube List
- Worldsymposium 2021 Poster List
- Elaprase, INN-Idursulfase
- Specialty Pharmacy Drug List Specialty Medications List
- Annual Report)
- Idursulfase Treatment of Hunter Syndrome in Children
- Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
- 2019 Medicaid Preapproval Criteria
- CHMP Agenda of the 19-22 July 2021 Meeting
- Product Monograph